Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07825701 | Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT Mutations | available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07614048 | Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS | available | — | — | Providence Health & ServicesOTHER | 0 | Jul 23, 2026 |
| clinicaltrials |
| NCT06948955 | Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors | available | — | — | Cogent Biosciences, Inc.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07612930 | Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy | available | — | — | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.INDUSTRY | 0 | May 29, 2026 | clinicaltrials |
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT01916148 | 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia | available | — | — | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04091295 | BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast | available | — | — | Aveni FoundationOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06872489 | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors | available | — | — | Second Life TherapeuticsINDUSTRY | 0 | Jul 23, 2025 | clinicaltrials |
| NCT06370013 | Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors | available | — | — | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02209441 | Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer | available | — | — | Chinese Academy of Medical SciencesOTHER | 0 | Aug 6, 2014 | clinicaltrials |
| NCT01786850 | Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer | available | — | — | University of Roma La SapienzaOTHER | 1 | Jun 18, 2014 | clinicaltrials |
| NCT01267461 | Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells | available | — | — | Meir Medical CenterOTHER | 0 | Aug 10, 2012 | clinicaltrials |
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials